Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference

Nexalin Technology, Inc. has announced that two clinical abstracts showcasing preliminary results from its proprietary DIFS™ treatment platform have been accepted for presentation at the 2026 NYC Neuromodulation Conference. The abstracts highlight significant improvements in anxiety, depression, insomnia, and quality of life from an 8-week clinical trial. Key findings include a 77.8% anxiety response rate without serious adverse events. The CEO emphasized that this acceptance marks a milestone for their non-invasive neurostimulation technology as they prepare for global commercial initiatives, particularly in Brazil where the study was conducted.